Observational study to determine the type of patient with cervical dystonia that responds best to botulinum toxin treatment

An international observational study to define factors influencing response to one Botulinum Toxin Type A (BoNT-A) injection cycle in subjects suffering from idiopathic cervical dystonia.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ANZCTR

Registry ID

ACTRN12609000800224

Enrollment

Registered

2009-09-15

Start date

2009-02-24

Completion date

Unknown

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

The primary purpose of this study is to determine which patients who suffer from cervical dystonia respond the best to botulinum toxin treatment.

Interventions

Botulinum Toxin Type A (BoNT-A) for idiopathic cervical dystonia. BoNT-A is able to stop nerves stimulating muscles thus providing a way of relaxing muscles. BoNT-A is administered by intramuscular injections with a duration of action of between 12 to 16 weeks. Observations will be made at 3-6 weeks post injection and again at the time of re-injection (12-16 weeks). The dosage given to the patient will be at the clinician's discretion.

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Greater than or equal to 18 years of age with idiopathic cervical dystonia. Toronto Western Spasmodic Torticollis Rating Scale score of greater than or equal to 15 and at least 12 weeks since last BoNT-A Injection.

Exclusion criteria

Contraindication to BoNT-A Secondary cervical dystonia

Outcome results